Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going

Stock Information for Monopar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Monopar Therapeutics Inc.

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.